logo-loader
Pressure BioSciences Inc.

Pressure BioSciences wins first customer for its water-soluble CBD manufacturing system

The BaroShear K45 system fixes a critical problem facing CBD manufacturers: the poor water solubility of CBD oil

thc and cbd oil
The system improves the effectiveness of CBD dosing as well as absorption

Pressure BioSciences Inc (OTCMKTS:PBIO) has won the first customer for its water-soluble CBD manufacturing system, the BaroShear K45, it announced Thursday.

The BaroShear K45 system is based on the company’s Ultra Sheer Technology platform, which applies high-pressure much greater than 20,000 pounds per square inch to create nano-scale emulsion mixtures of otherwise immiscible fluids — like oils and water — that results in stable homogenized products called nanoemulsions.

Given this ability, the BaroShear K45 system is a powerful next generation nano-emulsification system designed to fix a critical problem facing CBD manufacturers: the poor water solubility of CBD oil.

READ: Pressure BioSciences inks second protein manufacturing contract with multi-billion dollar biotherapeutics company

Nano CBD Cosmetics LLC is Pressure BioSciences’ first customer, and founder Christopher Holden called the BaroShear system “groundbreaking technology.”

Dan Jorgenson, a director at Nano CBD, added that “nano-emulsified CBD products will soon become established as an important new standard in the industry.”

The new form of CBD oil created with the help of the BaroShear K45 system disperses instantly, thus making it easier for the oil to be added to sodas and seltzers, vitamin-infused sports drinks and beer.

Improving CBD absorrption rate

Pressure BioSciences, based in South Easton, Massachusetts, also said the system improves the effectiveness of CBD dosing as well as absorption.

The current absorption rate for orally consumed CBD is typically below 10%, but the company said the BaroShear K45 system could deliver up to a 90% rate.

Pressure BioSciences CEO Richard Schumacher said the company expects demand for the system to grow.

“We are also pleased to announce that we are in advanced discussions with over a half dozen additional companies about the potential of their purchasing the BaroShear K45 processing system,” Schumacher said.

“Since we plan to make only about a dozen processing systems in our initial manufacturing run, we are optimistic that purchase orders will be received for all available BaroShear K45 systems well before our original forecast of September 30, 2019. This is truly an exciting time to be a stakeholder in PBI.”

The company’s stock recently traded down 1.6% to $3 a share on the OTC Markets.

Contact the author: [email protected]

Follow him on Twitter @PatrickMGraham

Quick facts: Pressure BioSciences Inc.

Price: $3.24

Market: OTCQB
Market Cap: $6.28 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Pressure BioSciences Inc. named herein, including the promotion by the Company of Pressure BioSciences Inc. in any Content on the Site, the...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Full interview: Pressure BioSciences CEO sees potential opportunity to enter...

Pressure BioSciences Inc (OTCMKTS:PBIO) CEO Ric Schumacher tells Proactive the medical device company's signature Pressure Cycling Technology (PCT) platform has been highlighted by scientists in China and Australia, which Schumacher says could eventually propel the company into the clinical...

1 week, 3 days ago

2 min read